Loading
Celularity
Celularity makes cell therapies and other products from the placenta after birth. It developed a ready-made natural killer cell therapy that was tested in acute myeloid leukaemia and glioblastoma, but the company now describes its main focus as diseases of ageing rather than cancer.
Also called: Celularity Inc
Overview
Celularity, listed on Nasdaq as CELU and based in Florham Park, New Jersey, develops placenta-derived cell therapies and biomaterials. Its own timeline traces it to Anthrogenesis, founded in 1998, which merged with Celgene in 2002; Celularity was spun out in 2017 and became a public company in 2021. Its NK cell platform page describes CYNK-001 as a cryopreserved, allogeneic, off-the-shelf natural killer cell therapy and lists clinical programmes in newly diagnosed acute myeloid leukaemia (NCT04310592) and glioblastoma (NCT04489420), as well as multiple myeloma and COVID-19. The current pipeline page leads with unmodified placental mesenchymal-like cells for Crohn's disease, diabetic foot ulcers and facioscapulohumeral muscular dystrophy, and lists an early-stage engineered T cell programme for solid tumours. The company describes its targets as age-related diseases.
Notes
- Founded is the 2017 spin-out year on the company's timeline; its predecessor Anthrogenesis dates from 1998. The status and results of the CYNK-001 trials were not checked, and those trials are not yet records in OnCo. The solid tumour T cell programme has no named indication or phase on the pipeline page. HQ is the business address in SEC EDGAR.
Connected
5Similar pages
cancers
fronts
technologies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
celularity.com · 5
A source that has moved or gone is reported by the weekly link check. /audit/